Stay updated on Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial
Sign up to get notified when there's something new on the Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial page.

Latest updates to the Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial page
- Check6 days agoChange DetectedThe site footer’s revision number changed from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check13 days agoChange DetectedThe site footer revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedA new revision entry v3.7.0 was added to the study's history, and the previous revision v3.6.6 was removed.SummaryDifference0.1%

- Check55 days agoChange DetectedA new entry for Revision: v3.6.6 was added to the Study Record History, replacing Revision: v3.6.5. This indicates a site release update applied to the ClinicalTrials.gov records.SummaryDifference0.1%

- Check76 days agoChange DetectedA new revision entry v3.6.5 was added to the study record history, indicating an update to the page, and the previous revision v3.6.4 was removed from the visible history.SummaryDifference0.1%

- Check91 days agoChange DetectedThe study's record history now includes a new Revision: v3.6.4 entry, replacing the previous Revision: v3.6.3 in the version list.SummaryDifference0.1%

Stay in the know with updates to Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial page.